Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE ‐O Trial
Authors' conclusion
In this post hoc analysis from the AMPLITUDE-O trial, changes in LDL cholesterol together with UACR but not weight were estimated to statistically account for a modest portion of the reduction in risk of MACE with efpeglenatide.
Study context
- Population
- Individuals with T2D and established CVD or kidney disease
- Participants
- 4,076 individuals
- Comparison
- Efpeglenatide vs placebo
- Primary endpoint
- Proportion of efpeglenatide's effect on MACE statistically explained by changes in measured clinical variables and biomarkers
Methodological detailsexploratory mediation analysis, post hoc
- Exploratory mediation analysis
- Post hoc
Primary result
As reported in the abstract
Proportion of efpeglenatide's effect on MACE explained (mediation)
- Univariable: change in HbA1c
- 14%
- Univariable: change in LDL-C
- 11%
- Univariable: change in UACR
- 16%
- Univariable: change in amylase
- 10%
- Multivariable: LDL-C together with UACR
- 29.6%
Further findings
Variables modified by efpeglenatide
- Change in HbA1c, weight, pulse pressure, LDL-C, UACR, eGFR, heart rate, lipase and amylase were modified by efpeglenatide
Parent trial: MACE · median follow-up 1.81 years
- Efpeglenatide reduced major cardiovascular events vs placebo
- 27%
Original publication
Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE ‐O Trial. Diabetes Obes Metab. Published 1 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →